The UCSF Helen Diller Family Comprehensive Cancer Center brings experts from across cancer specialties within UCSF’s network and beyond to revolutionize how cancer is treated. UCSF Parker Institute investigators continue building on the university’s deep scientific expertise to advance research in T-cell therapies, CRISPR technology, the biology of the immune microenvironment and precision treatments. Kole Roybal, PhD | Director Lawrence Fong, MD | Co-Director All Investigators Related Press Release PICI, JDRF and Helmsley Trust Form Research Initiative Announcement PICI Young Investigator Retreat 2019 Announcement, Press Release Parker Institute Awards $525,000 to Advance Diverse Talent in Cancer Research Announcement PICI Network Investigators Propel Immunotherapy Progress at SITC 2024 Announcement, Press Release PICI’s 2024 Fall Scientific Retreat Ignites Collaboration to Accelerate Cancer Immunotherapy Announcement, Press Release Parker Institute Welcomes New Co-Directors for PICI Centers at Stanford, UCSF & Penn Announcement, Press Release Parker Institute Commits Additional $125M for Audacious Mission to Cure Cancer Announcement, Press Release The Parker Institute for Cancer Immunotherapy Awards More Than $1 Million to Four Early Career Investigators Announcement Behind the Breakthrough: An Interview with Carl June, the Father of CAR T-Cell Therapy
Announcement, Press Release Parker Institute Awards $525,000 to Advance Diverse Talent in Cancer Research
Announcement, Press Release PICI’s 2024 Fall Scientific Retreat Ignites Collaboration to Accelerate Cancer Immunotherapy
Announcement, Press Release Parker Institute Welcomes New Co-Directors for PICI Centers at Stanford, UCSF & Penn
Announcement, Press Release Parker Institute Commits Additional $125M for Audacious Mission to Cure Cancer
Announcement, Press Release The Parker Institute for Cancer Immunotherapy Awards More Than $1 Million to Four Early Career Investigators